Cantrixil proves highly effective at killing human ovarian stem cells in pre-clinical study

US-Australian drug discovery company, Novogen Ltd, and its subsidiary, CanTx, Inc., and Yale University, on March 27 released pre-clinical data on experimental anti-cancer drug, Cantrixil. The data was presented as an oral presentation by Professor Gil Mor MD PhD of Yale Medical School to the 62nd Annual Scientific Meeting of the Society of Reproductive Investigation in San Francisco, CA.



from The Medical News http://ift.tt/1ErEkDk